drugset / Trial / NCT00551096

Gemcitabine/Capecitabine/ZD6474 in Advanced Solid Tumors

NCT00551096

NaSingle-groupOpen-labelTreatment

Summary

Zactima will be used in this study to determine the highest dose that can be given safely as well as the side effects of Zactima when in combination with two FDA approved drugs; gemcitabine and capecitabine. This combination will be given to patients with advanced solid tumors. Once the highest dose of the combination has been determined, additional patients with biliary cancers (cholangiocarcinomas and gallbladder cancer) and locally advanced or metastatic pancreatic cancer will be treated at the highest determined dose for further studies.

Timeline

Start
2007-10
Primary completion
2013-05
Completion
2013-05

Drugs

EvaluationDrugModalityDoseRoute
Subject Vandetanib Small molecule 200 mg Oral
Subject Vandetanib Small molecule 300 mg Oral
Background Capecitabine Small molecule 1660 mg/m2 Oral
Background Gemcitabine Small molecule 1000 mg/m2 Intravenous